These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 14679270

  • 1. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group.
    JAMA; 2003 Dec 17; 290(23):3073-80. PubMed ID: 14679270
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan 17; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 3. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 Jan 17; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 4. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group.
    Int J Dermatol; 2006 May 17; 45(5):605-14. PubMed ID: 16700803
    [Abstract] [Full Text] [Related]

  • 5. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.
    BMC Dermatol; 2005 Dec 16; 5():13. PubMed ID: 16359548
    [Abstract] [Full Text] [Related]

  • 6. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group.
    J Am Acad Dermatol; 2005 Mar 16; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [Abstract] [Full Text] [Related]

  • 7. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLEAR Multinational Study Group.
    Br J Dermatol; 2006 Jul 16; 155(1):170-81. PubMed ID: 16792770
    [Abstract] [Full Text] [Related]

  • 8. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Nov 16; 10(46):1-233, i-iv. PubMed ID: 17083854
    [Abstract] [Full Text] [Related]

  • 9. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D, Efalizumab Study Group.
    N Engl J Med; 2003 Nov 20; 349(21):2004-13. PubMed ID: 14627785
    [Abstract] [Full Text] [Related]

  • 10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 20; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 11. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 20; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 May 20; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 20; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 14. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug 20; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 20; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 01; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 18. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul 01; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 19. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
    Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP.
    J Drugs Dermatol; 2004 Jul 01; 3(6):614-24. PubMed ID: 15624744
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.